Cited by 697Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsAdvanced Glycation End Products research

Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease

Open access
Pugazhenthi, Subbiah, Qin, Limei, Reddy, P. Hemachandra·2017·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

Abstract

Cognitive decline in chronic diabetic patients is a less investigated topic. Diabetes and obesity are among the modifiable risk factors for Alzheimer's disease (AD), the most common form of dementia. Studies have identified several overlapping neurodegenerative mechanisms, including oxidative stress, mitochondrial dysfunction, and inflammation that are observed in these disorders. Advanced glycation end products generated by chronic hyperglycemia and their receptor RAGE provide critical links between diabetes and AD. Peripheral inflammation observed in obesity leads to insulin resistance and type 2 diabetes. Although the brain is an immune-privileged organ, cross-talks between peripheral and central inflammation have been reported. Damage to the blood brain barrier (BBB) as seen with aging can lead to infiltration of immune cells into the brain, leading to the exacerbation of central inflammation. Neuroinflammation, which has emerged as an important cause of cognitive dysfunction, could provide a central mechanism for aging-associated ailments. To further add to these injuries, adult neurogenesis that provides neuronal plasticity is also impaired in the diabetic brain. This review discusses these molecular mechanisms that link obesity, diabetes and AD. This article is part of a Special Issue entitled: Oxidative Stress and Mitochondrial Quality in Diabetes/Obesity and Critical Illness Spectrum of Diseases - edited by P. Hemachandra Reddy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbadis.2016.04.017

Cites

142 of 142 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Binding of AGEs and amyloid beta to RAGE causes additional oxidative stress that contributes to neuronal death and vascular dementia in Alzheimer disease.

    “AGE and Aβ binding to RAGE leads to further oxidative stress that contributes to neuronal death and vascular dementia in AD45–48.”

    From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [45]

    Section 6 (page unavailable) describes RAGE as a putative receptor for Aβ and says AGEs increase Aβ cytotoxicity; it also links RAGE activity to cognitive decline in AD mice. It does not state that AGE and Aβ binding to RAGE causes oxidative stress, or that this pathway contributes to neuronal death and vascular dementia in AD. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • Given the similarity in mitochondrial dysfunction observed in obesity, type 2 diabetes, and AD, it is reasonable to hypothesize that lifestyle interventions, if implemented in midlife or earlier, may protect against the mitochondrial dysfunction evident in AD.

    “Given the similarity in mitochondrial dysfunction observed in obesity, type 2 diabetes, and AD [184,185,186,187], it is reasonable to hypothesize that these lifestyle interventions, if implemented in midlife or earlier, may protect against the mitochondrial dysfunction evident in AD.”
  • Disrupted immune function is a potential link between metabolic and neurodegenerative disease states.

    “Intriguingly, it has been suggested that disrupted immune function is a potential link between these disease states (Pugazhenthi et al., 2017; Newcombe et al., 2018).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Pugazhenthi, S., Qin, L., & Reddy, P. H.
Affiliations
  • Veterans Health Administration (US)
  • Texas Tech University Health Sciences Center (US)
Corresponding author
Pugazhenthi, Subbiah
Venue
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Publisher
Elsevier BV
Published
2017-05
Volume
1863
Issue
5
Pages
1037-1045
ISSN
0925-4439 (ISSN-L)
OpenAlex
W2347041376
Cited by
697
References
142
Citations by year
2026: 52 · 2025: 81 · 2024: 100 · 2023: 96 · 2022: 111 · 2021: 88 · 2020: 75 · 2019: 34 · 2018: 27 · 2017: 26 · 2016: 6 · 2014: 1
FWCI
3.64
Type
journal article
Language
en
Open access
Locations
  • Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Merit Review (NEUD-004-07F)
  • NIH (AG042178, AG047812)
  • Garrison Family Foundation
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
Keywords
Alzheimer's disease, obesity, type 2 diabetes, neurodegeneration, neuroinflammation, oxidative stress, mitochondrial dysfunction, advanced glycation end products, RAGE, hyperglycemia, insulin resistance, blood-brain barrier, adult neurogenesis, cognitive decline
MeSH terms
Receptor for Advanced Glycation End Products, Alzheimer Disease, Animals, Blood-Brain Barrier, Brain, Diabetes Mellitus, Humans, Inflammation, Mitochondria, Obesity, Glycation End Products, Advanced, Oxidative Stress, Diabetes Complications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review